NCT06853444View on ClinicalTrials.gov

A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

May 8, 2025

Primary Completion Date

March 31, 2026

Study Completion Date

April 30, 2027

Conditions
Immune Thrombocytopenia (ITP)
Interventions
DRUG

ESG206

Administered via intravenous (IV) infusion

DRUG

ESG206

Administered via intravenous (IV) infusion

DRUG

ESG206

Administered via intravenous (IV) infusion

DRUG

ESG206

Administered via intravenous (IV) infusion

Trial Locations (1)

250012

RECRUITING

Qilu Hospital of Shandong University, Jinan

All Listed Sponsors
lead

Shanghai Escugen Biotechnology Co., Ltd

INDUSTRY